The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) reports 72% of facilities manufacturing APIs for American drugs are overseas, with 13% in China. Download our white paper where we discuss effective strategies to secure and de-risk pharmaceutical supply chains and reveal how Curia assures the continual production of urgently needed drugs.View resource
More from Curia
When a drug substance requires a parenteral formulation to administer it, there are key factors to consider when choosing the ideal CDMO partner.